[Current viewpoints in the treatment of epilepsies: role of new antiepileptics?].

Although standard anticonvulsants are effective in achieving complete seizure control in the majority of patients, an appreciable proportion (about 20 to 25%) is at least in part resistant to conventional pharmacotherapy. Efficacy of carbamazepine, phenytoin, phenobarbital and valproate is very similar. Should one drug fail because of inadequate efficacy and unacceptable adverse effects, an alternative monotherapy should be used. Surgical treatment is a possible therapeutic option for only some of these patients. The development of newer, more effective drugs, such as vigabatrin, lamotrigine, gabapentin and oxcarbazepine, for monotherapy is desirable. The search for new antiepileptic agents is reasonable in order to reduce the proportion of drug-resistant patients. The choice of conventional or new drugs should include not only expected efficacy and risk of adverse effects, but also pharmacokinetic properties and expense. Consequently, no general rule is appropriate, and each decision and recommendation for treatment should be individualized.